# Sichuan Clover Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sichuan-clover-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.cloverbiopharma.com
- Total disclosed funding: $297M
- Latest round: Series C (Feb 22, 2021)
- Investors on record: 11

## About

Based in Chengdu, China and founded in 2007 through GenHunter by Dr.Liang, Sichuan Clover Biopharmaceuticals, Inc., a subsidiary of Clover Biopharmaceuticals, Ltd., is a global clinical-stage biotechnology company committed to developing novel vaccines and biological therapeutic candidates to address life-threatening diseases and public health threats. The company has established a partnership with CEPI and Dynavax to deliver a safe and effective COVID-19 vaccine to countries and regions around the world affected by the COVID-19 pandemic. 

The company has a commercial manufacturing facility in Chanxing and Chengdu, suppling R&D and clinical programs. In 2021, Sichuan Clover Biopharmaceuticals, Inc. raised USD 230 million in Series C funding co-led by returning investor GL Ventures and new investor Temasek Holdings, with participation from other investors.  The company raised USD 315 million across several funding rounds since 2011 and has filed for a Hong Kong IPO in 2021

The company’s product pipeline consists of six Trimer-Tag© subunit vaccine candidates, twoTrimer-Tag© oncology product candidates and three Fc-fusion product candidates covering 13 indications. The company’s flagship Trimer-Tag© technology is a product development platform for the creation of vaccines and therapies. This technology helps to trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biological targets.  Clover produces covalently-trimerized fusion proteins to target previous pathways and has also developed SCB-2019 (CpG 1018/Alum), a vaccine candidate for SARS-CoV-2 infections. Additionally, the company is conducting vaccine discovery programs for other infections including rabies, RSV, influenza, and HIV. 

Apart from the COVID-19 vaccine, Clover has designed and developed SCB-313 for the treatment of intracavitary malignancies including malignant ascites (MA), malignant pleural effusion (MPE), and peritoneal carcinomatosis (PC), as well as additional cancer indications; along with SCB-808 for rheumatic diseases, SCB-420 for the treatment of certain large market ophthalmologic diseases, including wet age-related macular degeneration (wAMD), and SCB-219 for CIT(chemotherapy-induced thrombocytopenia) and ITP (immune thrombocytopenic purpura). 

The company plans to commercialize SCB-2019 (CpG 1018/Alum) as one of the first protein-based COVID-19 vaccines and subsequently submit applications to the EMA, the NMPA, and the WHO by the second half of 2021 and launch the product by the end of 2021. Clover also plans to capture a market of 15 billion doses required through 2026. The firm also plans to submit SCB-808 for approval to the NDA and NMPA in 2022.  The company plans on utilizing the proceeds from Series C funding for the development and expansion of protein-based vaccines and biologic cancer therapies.

## Funding rounds

- Series C, Feb 22, 2021, $230M — OrbiMed Advisors, Temasek Holdings, Delos Capital Partners, Oceanpine Capital, GL Ventures
- Series B, Jun 8, 2020, $24M — GL Ventures
- Series B, Nov 27, 2019, $43M — Zhongguancun Venture Capital, Delos Capital Partners, Lapam Capital, Hangzhou Jinlong Group, Betta Capital, Sichuan Health Care Industry Fund
- Series A, Jan 15, 2017 — Qiaojing Capital

## Investors

- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Series A
- Zhongguancun Venture Capital (https://capitalatlas.ai/funds/zhongguancun-venture-capital) — Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series B, Series C
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- Hangzhou Jinlong Group — Series B
- Betta Capital — Series B
- Sichuan Health Care Industry Fund — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Temasek Holdings — Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C